Table 2.
Frequency of remission in psoriatic arthritis (PsA) patients and rheumatoid arthritis (RA) controls receiving adalimumab (ADA), time to remission, and duration of remission after ADA dose reduction
| Psoriatic arthritis 76 patients | Rheumatoid arthritis 55 patients | P value | |
|---|---|---|---|
| Overall remission (N/%) | 53 (69.7%) | 17 (30.9%) | 0.019 |
| Combined methotrexate (N/%) | 46 (86.7%) | 16/17 (94.1%) | NS |
| Remission by PsA pattern | |||
| • Peripheral | 32 (71.1%) | ||
| • Axial | 5 (71.4%) | ||
| • Mixed | 16 (66.6%) | ||
| Time to remission (months/mean ± SD) | 5.1 ± 1.2 | 6.3 ± 1.6 | NS |
| PsA remission after ADA dose reduction (N/%) | 47 (88.6%) | 3 (17.6%) | 0.016 |
| Relapse by PsA pattern (N/%) | |||
| • Peripheral | 3 (9.3%) | ||
| • Axial | 1 (20%) | ||
| • Mixed | 2 (12.5%) | ||
| Time to relapse (months/mean ± SD) | 8.3 ± 3.4 | 7.2 ± 4.2 | NS |
| Duration of follow-up (months/mean ± SD) | 28.9 ± 8.4 | 24.2 ± 6.4 | NS |
Abbreviations: ADA, adalimumab; PsA, Psoriatic arthritis; N, number; NS, not significant; SD, standard deviation.